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The new age of renal biomarkers – does SDMA solve all of our 
problems? 
Abstract 
Within clinical small animal practice, diagnosis of both chronic kidney 
disease (CKD) and acute kidney injury (AKI) is common. To assess renal function, 
measurement of glomerular filtration rate (GFR) is considered the gold 
standard. Currently, routine tests of kidney function include surrogate markers of 
GFR such as serum creatinine, and urea, each with their own limitations, whilst urine 
protein to creatinine ratio gives an indication of glomerular and tubular handling of 
protein, and urine specific gravity information about urine concentrating ability by the 
kidney.  These parameters are used together with historical and physical examination 
data to give a diagnosis of kidney disease following which creatinine, proteinuria and 
blood pressure are used to stage CKD and, together with urine output, grade AKI 
according to the International Renal Interest Society (IRIS). However, there has been 
much concern that creatinine is insensitive when used to indicate early decline in 
renal function and this has highlighted the need for additional methods of diagnosing 
and monitoring these patients, with the potential to allow earlier therapeutic 
intervention. Symmetric dimethylaginine (SDMA) is a novel biomarker, which has 
been shown to perform as a surrogate marker of GFR in small animals. This 
article will review current research on SDMA and the ways in which it may be utilised 
in small animal practice; current research supports the use of SDMA as a screening 
test for detection of early CKD according to IRIS guidelines, but further research is 
required in to the usefulness of SDMA as a tool for monitoring disease and the effect 






Renal disease encompasses both chronic kidney disease (CKD) and acute kidney injury 
(AKI) and affects both cats and dogs, with CKD in particular being a common diagnosis in 
general practice (Bartlett et al. 2010; O’Neil et al. 2013; O’Neil et al. 2015).  AKI is 
characterised by a rapid decrease in glomerular filtration rate (GFR), for which there are a 
wide array of potential aetiologies both community and hospital acquired, though in many 
instances an underlying aetiology is not identified (Khan & 
Khan 2015).  In contrast, CKD is defined as the presence of functional or structural 
abnormalities affecting one or both kidneys for a period of at least 3 months. Again, although 
certain specific conditions can be identified e.g. polycystic kidney disease, frequently the 
major histopathological finding is non-specific tubulointerstitial nephritis particularly in 
cats. (Chakrabarti et al. 2012; Reynolds & Lefebvre 2013). 
In veterinary medicine, it is routine to use a combination of plasma or serum creatinine (Scr) 
and urea concentrations with urine specific gravity and protein content to assess renal 
function. Limitations of these parameters mean that the early diagnosis of 
CKD remains challenging. Nevertheless, this is of significant clinical importance 
as early intervention may slow the rate of progression of disease, potentially improving 
quality of life and prolonging survival (Grauer 2005; Tenhündfeld et al. 2009). In 
addition, early diagnosis possibly gives the best chance of identifying and treating the 
underlying cause. This has led to the advent of a new age of research with the aim of 
identifying biomarkers of renal function that can be utilised to diagnose early disease. 
  
Current methods of assessing kidney function in clinical practice 
The rate of glomerular filtration (GFR) is defined as the volume of ultra-filtrate formed in the 
nephrons of both kidneys per unit of time and is directly correlated to the functional renal 
mass (DiBartola 2012; Kerl & Cook 2005).Therefore, measuring the clearance of a marker of 
filtration is considered the best method for assessing renal functional mass (Kerl & 
Cook 2005). The exogenous filtration marker inulin is considered the gold standard marker 
for determination of GFR via urinary clearance (Haller et al. 1998). However, determination 
of urinary clearance is challenging clinically compared to obtaining blood 
samples and therefore plasma clearance of a marker, typically iohexol, remains the 
most useful filtration test for clinical practice (Finch 2014). Within clinical practice, serum or 
plasma creatinine and urea concentration combined with urine specific gravity (USG) are the 
most frequently used markers of renal function, being easily quantified from a single blood or 
urine sample. Having identified azotaemia on a clinical biochemistry,  pre and post-renal 
azotaemia should always be excluded before attributing azotaemia to intrinsic kidney disease. 
It is widely reported that in dogs with pre-renal azotaemia, USG should exceed 1.030 whilst 
in cats it should exceed 1.035 (Wamsley & Alleman 2017). However, this is complicated by 
the fact that cats may also maintain urine concentrating ability despite significant renal mass 
reduction (Adams et al. 1993; Mathur et al. 2002). Anecdotally, cats with early CKD may still 
maintain some degree of urine concentrating ability (USG 1.030-1.045) even in the face of 
mild azotaemia. 
Scr concentration is an indirect estimate of glomerular filtration. Creatinine, a by-product of 
endogenous muscle metabolism (Linnetz & Graves 2010), is filtered at the glomerulus and 
negligible renal secretion or reabsorption occurs in healthy animals (Finco et 
al. 1991). Plasma or serum concentrations have been shown to correlate inversely with 
GFR (Finch 2014). However, the use of Scr concentration as a surrogate marker of GFR 
has limitations; two of the most clinically relevant being non-renal influences and poor 
sensitivity to early disease. 
Non-renal influences on serum creatinine 
Circulating creatinine is a breakdown product  of creatine phosphate in muscle and 
therefore Scr concentration will depend on muscle mass and may be significantly decreased 
in animals with low muscle mass such as geriatric or immature individuals or in (Braun et 
al. 2003). Scr is also influenced by age and breed in dogs and, to a lesser degree cats (e.g. 
Birman) (Gunn-Moore et al. 2002), however breed specific reference intervals are not 
routinely used (Reynolds et al. 2010; Misbach et al. 2014; Rørtveit et al. 2015). Data 
suggests that plasma creatinine concentrations increase gradually over the first year of life in 
dogs but then remain stable(Braun et al. 2003) whilst in kittens creatinine concentrations are 
relatively high at birth but are similar to or lower than adults by 8 weeks of age (Levy et al 
2006). Furthermore, studies have shown that Scr can be affected by diet with increases 
in Scr  following meat ingestion (Watson et al. 1981). A recent study of healthy geriatric cats 
aged between 8 and 19 years, revealed cats below 12 years had higher total 
lean body mass determined by dual-energy X-ray absorptiometry, Scr and GFR compared 
with cats over 15 years old (Hall et al. 2014b). This is of particular clinical relevance with 
the demographic of cats being monitored for CKD generally being geriatric. To allow for 
these limitations, it is recommended that Scr is always measured on a fasted blood sample 
and interpreted considering the breed, muscle mass and age of the animal. In general, non-
renal disease conditions are believed to have minmal influence on creatinine concentration 
aside from their potential impact on muscle condition. The exception is thyroid 
disorders, where the alteration in endogenous production of creatinine may have an impact 
on plasma creatinine concentration (Panciera & Lefebvre 2009).  
The interpretation of Scr may also be influenced by analytical variability (Hokamp & 
Nabity 2016). Within human medicine, the clinical implications of inconsistencies between 
instruments and laboratories, have been recognised and the standardisation of Scr results 
between laboratories is a priority, with consensus based International Organisation for 
Standardisation (ISO) standards being made available (Peake & 
Whiting 2006). However, similar standardisation has not been implemented in veterinary 
medicine. A recent study of reference laboratories in Northern Europe revealed laboratories 
to have good precision amongst instruments but revealed large variation between different 
laboratories (Ulleberg et al. 2011) highlighting the importance of consistency in the 




Sensitivity of creatinine as a maker of glomerular filtration rate 
Perhaps the most widely reported limitation of using a marker of GFR to assess renal 
function and the greatest challenge in early diagnosis of CKD is the curvilinear relationship 
between the marker and GFR, specifically the steep curvilinear relationship between Scr and 
GFR (Figure 1). Consequently, a significant reduction in GFR from normal is required before 
a corresponding increase in Scr is seen (Finch 2014) whilst in advanced disease, a 
smallhange in GFR will have a large impact on Scr making Scr a useful marker 
of progression in the later stages of CKD. 
Increases in creatinine can be identified in early disease but the changes are small, often still 
within reference interval and potentially below the precision of instruments measuring 
creatinine. Nevertheless, such subtle changes and trending of creatinine within reference 
interval can be used to determine change in GFR with time, providing the patient’s muscle 
mass, volume and hydration status remains constant (Hokamp & Nabity 2016; Nabity et al. 
2015). Creatinine is widely used in this context particularly with reference to acute kidney 
injury in human (RIFLE classification (Risk of renal dysfunction, Injury to the kidney, Failure 
of renal failure, Loss of renal function and End-stage renal disease) and Acute Kidney Injury 
Network (AKIN)) (Lopes & Jorge 2013) and veterinary medicine (IRIS 2013).   
  
Use of creatinine for IRIS grading of acute kidney injury and staging of chronic kidney 
disease 
Within veterinary medicine, IRIS recommends the use of fasting blood creatinine 
concentration to grade AKI and stage CKD in cats and dogs (IRIS 2019). The 
presentation of animals with AKI is frequently reported to be different to that in people, with 
animals often suffering a community acquired insult (e.g. toxin) rather than 
hospitalised acquired AKI. Such patients typically present with clinical signs referable to 
uraemia, and clinical biochemistry confirms azotaemia. In this situation, creatinine would be 
anticipated to perform well as a marker of GFR as creatinine values will fall on the steep 
region of the exponential relationship. However, IRIS grade I AKI includes non-
azotaemic animals with a progressive increase of 
greater than 26.5umol/L (0.3mg/dl from baseline creatinine concentration within a 48 hour 
period (IRIS 2013). This can aid early identification of AKI, for example in those patients who 
require monitoring after nephrotoxin ingestion and means that our recognition and therefore 
the prevalence of hospital acquired AKI is likely to increase.   
In both dogs and cats, a specific diagnosis of CKD is made on the basis of historical 
information, physical examination findings together with laboratory diagnostics and 
diagnostic imaging. The diagnosis of CKD must be made before IRIS staging can be 
applied. Based on creatinine the IRIS system defines stage 1 CKD as a non-
azotaemic animal (Scr < 125 umol/L, 1.4mg/dl in dogs; Scr <140 umol/L, 1.6 mg/dl in 
cats) with some other renal abnormality present: persistent inadequate urine concentrating 
ability with no identifiable non-renal cause, abnormal renal palpation or 
imaging, persistent proteinuria of renal origin, abnormal renal biopsy results or an increase in 
blood creatinine concentration in serially collected samples (IRIS 2019). For patients with 
more advanced stable CKD, it is more straight forward to identify CKD based solely on 
persistently increased creatinine concentration. However, the identification of IRIS 
stage 1 and stage 2 animals (Scr 125-180 umol/L, 1.4-2 mg/dl in dogs; Scr 140-250 umol/L, 
1.6-2.8 mg/dl in cats) where creatinine may be within laboratory reference interval, can be 
challenging and requires clinicians understand the importance of documenting trends 
in creatinine concentration within reference interval, in addition to evaluating for other clinical 
evidence of CKD. An early biomarker that eliminated the need to monitor trends and which 
had a high sensitivity to detect an early change in renal function for both acute and chronic 
disease, would have considerable clinical utility (Hokamp & Nabity 2016). 
  
History of symmetric dimethylarginine 
In the 1970s scientists investigated previously unclassified amino acids in human urine and 
identified a group of compounds which they classified as N-methylated derivatives of lysine 
and arginine. This group included NG, NG- dimethylarginine (asymmetrical dimethylarginine; 
ADMA) and NG, NtG- dimethylarginine (symmetrical dimethylarginine; SDMA) (Kakimoto & 
Akazawa 1970). Subsequently, it has become clear that SDMA and ADMA are produced in 
all cells through methylation of arginine residues, a post translational modification in which a 
methyl group is added to protein residues to alter their detection or activity , subsequently 
SDMA and ADMA are  released into the circulation during proteolysis (Bedford et al. 
2009; Kielstein et al. 2006). In humans, ADMA is primarily metabolised in the tissue 
by the enzyme dimethylarginine dimethylaminohydrolase, with renal clearance being 
estimated at 20% (Schwedhelm & Böger 2011). In contrast, although a small amount 
of hepatic clearance has been reported in people (Siroen et al. 2005), renal clearance of 
SDMA is estimated at 90% in people (Schwedhelm & Böger 2011), highlighting the suitability 
of SDMA as an endogenous kidney biomarker. Twenty years after SDMA and ADMA were 
first discovered, Vallance and 
colleagues (1992) identified their accumulation in human patients with renal failure 
and published a landmark paper focusing on the pathogenicity of ADMA via inhibition of 
nitric oxide (NO) synthase, hypothesising that ADMA may contribute to the complications of 
hypertension, immune dysfunction and cardiovascular disease, associated with human 
CKD. Consequently, until recently, research has focused on ADMA which has emerged as a 
cardiovascular risk factor (Zeller et al. 2008; Ronden et al. 2012). In contrast, for many years 
little attention was paid to SDMA..  However, in recent years, with the growing interest 
in novel biomarkers of renal function, research has focused on how SDMA may be 
utilised in veterinary clinical practice. 
  
Quantification of SDMA until recently has been the preserve of research studies due to the 
requirement for measurement by liquid-chromatography-mass spectrometry (LC-MS). 
However, since 2015, SDMA quantification has been available to practitioners worldwide 
through IDEXXa, a commercial veterinary diagnostic laboratory.  A notable 
advantage compared to creatinine therefore is the potential for reduced analytical variability 
given that a single company is offering this test. However, it should be noted that reducing 
analytical variability relies on a number of factors including variability of the immunoassay 
methodology, the environmental conditions of the laboratory and the instruments used within 
labs and appropriate internal quality control should be performed.  Reference intervals 
were initially generated using serum samples from a population of 120 clinically healthy, 
adult dogs aged between 1 and 15 years and of varying breeds and sex, with SDMA 
measured using LC-MS and results analysed with a nonparametric model, using a 2-sided 
95% confidence interval (Relford et al. 2016). The same methodology was used for 86 
clinically healthy adult cats, aged between 6 and 15 years and of varying breeds (Relford et 
al. 2016). Neither study included GFR 
measurement or necropsy evaluation.  Subsequently IDEXXa have developed a high-
throughput competitive immunoassay and usedthe LC-MS derived reference interval for 
clinically healthy animals in both species at ≤14ug/dl  (Relford et al. 2016). This patented 
technology uses anti-SDMA monoclonal antibody and glucose-6-phosphate dehydrogenase 
(G6PDH) conjugate to quantify SDMA in serum or plasma with an immunoassay. The anti-
SDMA antibody is reported to be specific to SDMA showing no significant cross reactivity 
with closely related molecules arginine, monomethyl arginine and ADMA(Patch et al. 2015). 
The analyte competes with a fixed amount of labelled analyte, SDMA-G6PDH conjugate, for 
a limited amount of anti-SDMA antibody. The amount of antibody bound to labelled analyte 
is a function of the total concentration of both labelled and unlabelled analyte and 
quantification is achieved through measuring label (G6PDH) activity. The accuracy of the 
assay was confirmed in human, feline and canine biological samples by comparison with LC-
MS analysis which is the gold standard for SDMA measurement (Patch et al. 
2015; Prusevich et al. 2015). In the UK, SDMA is currently quantified by 
immunoassay, although at USA IDEXX an LC-MS methodology is available for clinical 
research purposes. To date, studies that have been published have used both 
methodologies for SDMA quantification. Good agreement between methods (cats r=0.97, 
dogs r=0.97, humans r=0.99) has been reported in abstract form (Patch et al. 2015) and a 
recent comparison of paired samples from healthy geriatric cats attending two UK first 
opinion practices (n=19) also showed good agreement between methods (r=0.97, personal 
communication).  In 2018, IDEXX  released the option to perform SDMA quantification by 
immunoassay on their in-house Catalyst® analyser (IDEXX 2018). This in-house assay has 
been assessed in terms of performance in comparison to LC-MS, precision, analytical 
specificity and the impact of interfering substances and performs well. Further information 
about the validation of this assay can be found in the IDEXX white paper (IDEXX 2018). This 
development transitions SDMA measurement to be a bed-side test for the practitioner, 
therefore complementing creatinine as an in-house test of renal function. 
Other assays are commercially available including the DLD SDMA ELISA which was 
designed to detect SDMA in human serum and which has been shown to be less accurate 
and precise than the IDEXX SDMA immunoassay in macroscopically normal feline and 
canine serum, when compared to the reference method of LC-MS (Ernst et al. 2018).  No 
other comparisons of other commercially available assays have been 
published and therefore, based on the current literature, the IDEXX SDMA test is currently 
most suitable for use in a clinical setting.   
  
Non-renal influences on symmetric dimethylarginine (Specificity of SDMA) 
As previously discussed, non-renal influences are a significant limitation on serum 
creatinine, notably, the influence of muscle mass.  A recently published study reports that 
there will be some expected biological and individual day to day variability for SDMA, as for 
other analytes such as creatinine and that a critical difference of 5.98 ug/dl between serially 
obtained samples is required in dogs to be a genuine difference in SDMA using the high-
throughput immunoassay methodology (Kopke et al. 2018; Kopke et al. 2019) This study 
also demonstrated a decreased interindividual variability of serum SDMA when compared to 
creatinine which the authors attribute to the influence of lean body mass and age on 
creatinine. However, it should be noted that intraindividual and analytical variation were both 
higher for SDMA than creatinine. Overall, SDMA is considered a very stable analyte (4 days 
at room temperature, 14 days at 4°C or long-term when frozen) and can be measured on 
both serum (preferred) and plasma samples with no interference in quantification reported 
with lipaemia or icterus although severe haemolysis may cause a decrease in the measured 
result (Nabilty et al 2015). It is always recommended that patients are fasted prior to 
biochemical evaluation, however there is some evidence that SDMA is not influenced by 
recent protein ingestion (Hall et al 2014b). 
There is evidence that, unlike creatinine, SDMA is not influenced by muscle mass, showing 
no correlation with lean body mass in healthy adult dogs or geriatric cats (Hall et al. 2014a; 
Braff et al. 2014; Hall et al. 2015). Similar to Scr, age may be an influencing factor on SDMA 
although not after the onset of maturity. A single study in dogs from age 2 months to 1 year 
reported that SDMA did not correlate with body condition, age or weight (Nabity et al. 2015). 
However, young healthy dogs in this study did have plasma SDMA concentrations up to 16 
µg/dL.There is limited information in the published literature currently relating to the effect of 
breed in dogs and cats on SDMA values. One study has suggested that SDMA may be a 
more accurate reflection of renal function in Birman cats than creatinine concentration 
although direct GFR and renal imaging were not performed (Paltinieri et al. 2018). A recent 
study comparing serum SDMA concentrations in clinically healthy greyhounds to that 
in other breeds, concluded that greyhounds havesignificantly higher mean serum SDMA 
concentrations compared to dogs of other breeds (13.1 µg/dL and 10.2 
µg/dL respectively) (Liffmann et al 2018). A reference interval for serum SDMA 
concentration in greyhounds was established as 6.3-19.9 µg/dL. No effect of sex on SDMA 
has been reported. Overall, the data to date supports that for those patients with sarcopenia, 
SDMA is likely to provide a more accurate representation of GFR than creatinine and based 
on this concept, SDMA has been encorporated into the IRIS staging system. It demonstrates 
reduced variability across breeds of dogs again most likely related to alteration in body size 
and muscle mass and the inherent limitations of creatinine in this 
regard. However, some caution should be applied when interpreting the SDMA results in 
juvenile animals in practice when SDMA concentrations slightly higher than the normal 
reference interval may not indicate renal disease. 
  
It is particularly important to understand the possible non-renal influence of concurrent 
disease and drug administration on circulating SDMA.  Studies have reported that time of 
day, white coat effect and short-term administration of the angiotensin-converting-enzyme 
inhibitors enalapril and quinapril (0.5mg/kg per os q24hrs for 7 days), have no influence on 
circulating SDMA (Moesgaard et al. 2005; Moesgaard et al. 2007, Pedersen et al. 
2006). One study in dogs has shown no correlation of serum SDMA concentration 
with the presence/absence of myxomatous mitral valve disease or with 
the symptoms of ,or pharmacological therapy for, congestive heart failure (Savarese et al 
2018). Furthermore, no correlation has been found between the cardiac biomarker N-
terminal pro-brain natriuretic peptide or between the liver enzymes alkaline phosphatase, 
alanine transaminase or aspartate aminotransferase and SDMA concentrations in 
dogs, providing preliminary although not complete evidence that cardiac disease including 
hypertrophic cardiomyopathy in cats (Langhorn et al. 2017) and hepatic disease have limited 
effect on SDMA (Relford et al. 2016). However, there is conflicting information about the 
potential effect of neoplastic disease on SDMA values, with studies presented only in 
abstract form exploring this issue.One study reviewing dogs and cats with neoplastic disease 
that had undergone post-mortem examination identified that, when SDMA was elevated 
above the upper reference limit (> 14ugdl), there was histopathological evidence of CKD 
whilst creatinine was within reference interval in all but one of these patients (Yeramilli et al. 
2017). Another, which evaluated SDMA concentrations in dogs with lymphoma, some dogs 
had elevated SDMA concentrations whilst remaining non-azotaemic, and 
showed normalisation of their SDMA concentrations when they achieved clinical remission 
after chemotherapy (Abrams-Ogg et al. 2017). Concern was raised that, given that SDMA 
originates from all nucleated cells, large tumour burden could result in elevated SDMA 
concentration rather than reduced renal function. Further work is necessary to establish any 
potential relationship between SDMA concentrations and neoplasia. 
Other conditions which have undergone preliminary investigation include nephrolithiasis 
and diabetes mellitus. There is evidence that SDMA concentrations may be increased in 
cats with nephrolithiasis although it is likely that this reflects early alteration in renal function 
rather than a non-renal influence on SDMA (Hall et al. 2017). However, significantly lower 
SDMA concentrations were observed in cats with diabetes mellitus (n= 17) compared to 
controls (n=20) (Langhorn et al. 2018). This has also been reported in humans where lower 
serum SDMA concentrations have been reported in humans with poorly controlled type 2 
diabetes compared to control (Can et al. 2011; Dimitroulas et al. 2015) and warrants further 
investigation. 
A further area of current interest is the effect of thyroid status on SDMA concentrations. As 
previously discussed, aside from the effects of hyperthyroidism on GFR, creatinine has 
limitations for both hypo- and hyperthyroid patients given the alteration in muscle mass 
and potential alteration in production of creatinine with these conditions. A marker that 
accurately reflected GFR would be of particular utility in hyperthyroid cats where CKD is also 
commonly diagnosed. Studies demonstrate that it can take up to 3-6 months for creatinine to 
accurately reflect GFR after treatment of hyperthyroidism, at least partly due to muscle 
wasting and therefore SDMA offers an attractive alternative (Boag et al. 2007). A very small 
study, presented only in abstract form, raised concern that SDMA did not differentiate 
hyperthyroid cats with and without azotaemic CKD, but the study was substantially 
underpowered (Williams 2017). Peterson and colleagues (2018) reported SDMA 
concentrations in the lower half of the reference interval (≤10 µg/dl) in 71% of a population of 
untreated hyperthyroid cats (n=262) anhypothesised this was due to the increased GFR 
associated with a hyperthyroid state. Of interest, in those cats that went on to 
develop azotaemic CKD following 131I treatment (n=42), 33% had an elevated pre-treatment 
SDMA concentration (>14 µg/dl), showing poor sensitivity for predicting azotaemia (33.3%) 
but good specificity (97.7%). In the same study sCr at a cut off just below the upper limit of 
the reference interval (>1.9 mg/dl 167 µmol/L RI >2.1mg/dl 186 µmol/L), performed poorly 
with a test sensitivity of 11.9%, specificity was 84.4%. Results of this study indicate that a 
high SDMA raises concern for CKD in cats diagnosed with hyperthyroidism but that it is in no 
way a perfect test for prediction of the development of azotaemia after treatment of 
hyperthyroidism. Buresova and colleagues (2019) also examined the effect of 131I treatment 
on the renal parameters of a group of 47 client-owned cats. Of particular interest in this study 
was a subgroup of 10 cats in which GFR was estimated via exogenous creatinine 
clearance at 4-48hrs prior to 131I treatment (T0) and 1 month after treatment (T1). Correlation 
between GFR and serum SDMA concentration was low and not significant at T0 and T1(τb= -
0.35, P=.17 at TO and τb = -0.22, P=.41 at T1), whereas correlation between GFR 
and sCr was moderate and significant at both T0 and T1 (τb= -0.52, P= < .05 at TO and τb = -
0.53, P= < .05 at T1 ).. All 47 cats in the study remained non-azotaemic at T0 and T1, 
though a significant increase in median Scr concentrations between before and after 
treatment with no significant difference in median SDMA concentrations was observed. The 
authors conclude that neither Scr or SDMA perform well as renal biomarkers in hyperthyroid 
cats and that a mildly increased serum SDMA in a hyperthyroid cat should be interpreted 
with care considering concentrations may return to normal following treatment, as in 4 
of the 6 cats with elevated SDMA at T0. In a recent study examining changes in thyroid and 
renal function following bilateral thyroidectomy, SDMA was relatively higher in hyperthyroid 
cats compared to euthyroid or hypothyroid cats in a group of 68 client-owned cats (Covey et 
al. 2019). Of interest, this study reported a high number of discordant results. Thirty percent 
of samples had a creatinine within reference range (<177 µmol/L, <2.0 mg/dl) with an 
elevated SDMA (> 14µg/dL). Four of these samples were in hyperthyroid cats prior 
to treatment; the remaining 26 samples were cats following bilateral thyroidectomy. Five 
percent (8 cats) of the samples had a normal SDMA (≤ 14µg/dL) with a creatinine above 
reference range following bilateral thyroidectomy (in a euthyroid or hypothyroid 
state). Five of these cats had a concurrent measured USG, all of which were 
below 1.035, indicating a renal azotaemia. Data on the SDMA and creatinine plasma 
concentrations before and after thyroidectomy for individual cats was not available.  The 
authors conclude that it is likely thyroid status influences the concentrations of both 
creatinine and SDMA, relative to GFR but also to one another. We have many years of 
clinical experience interpreting creatinine concentrations in patients with altered thyroid 
function with studies exploring its limitations. These studies highlight that, further 
research and experience is required in order to expand our understanding of the effect of 
thyroid status on SDMA measurement in dogs and cats and with treatment for thyroid 
disorders. 
Within human medicine SDMA has been demonstrated to be upregulated in critically ill 
patients, especially in conditions of sepsis and to be independently associated with organ 
failure and death (Koch et al 2013). A preliminary study of 7 healthy control and 22 critically 
ill dogs with heterogeneous disease, excluding acute kidney injury, found no difference 
in median SDMA concentrations between critically ill and control dogs (Koster et al. 
2018).  However, this study did not specifically include septic dogs and is significantly 
underpowered and further larger studies examining this relationship are warranted. 
To summarise these studies provide preliminary evidence that some concurrent diseases 
may influence SDMA concentrations in cats and dogs and highlights the need for 
further research. Interestingly, within the literature, there are reports of animals who are 
considered to have normal renal function with elevated SDMA (Langhorn et al. 2018) and 
anecdotally this has been observed in clinical practice (authors personal communication). 
This highlights the importance of exploring the effects of concurrent disease and also 
documenting persistence of elevation in SDMA when using this parameter to make a 
diagnosis of early non-azotaemic CKD. 
  
Sensitivity of SDMA as a marker of GFR 
In an early meta-analysis of 18 studies providing a total of 2136 human patients, SDMA 
showed a strong negative correlation with GFR measured by inulin clearance (r=.85, P< 
.0001) (Kielstein et al. 2006). Similarly, in both dogs and cats serum SDMA has been shown 
to be an endogenous surrogate marker of GFR. In a study of 69 geriatric cats, serum SDMA 
concentrations were significantly increased in those cats with azotaemic CKD and were 
positively correlated with plasma creatinine (r = .741) (Jepson et al. 2008). In adolescent 
dogs with x-linked hereditary nephropathy (XLHN), both serum SDMA and Scr correlated 
strongly and inversely with GFR measured by exogenous plasma iohexol clearance (r= - .95, 
- .98 respectively) (Nabity et al. 2015) indeed suggesting that there was little to differentiate 
creatinine and SDMA as markers of GFR in this small and very specific population of 
dogs. Similarly, in a retrospective analysis of 10 client owned cats selected to give a range of 
GFRs, the reciprocal of serum SDMA and plasma creatinine showed a linear relationship 
with GFR measured by exogenous plasma iohexol clearance (R2= .82, .81 respectively P< 
.001) whether cats were azotaemic or not (Braff et al. 2014). Based on these studies, the 
relationships between SDMA and Scr and GFR are very similar. Both markers demonstrate 
an exponential relationship with GFR and as such will be subject to the same limitations in 
terms of detection of early decline in GFR. It is mainly on the basis of clinical longitudinal 
studies that the ability of SDMA to detect early decline in renal function has 
become apparent. To date studies that explore the potential benefits of trending SDMA as 
discussed for creatinine have not been performed but may hold potential merit. 
A recent abstract examined serum SDMA concentration in a group of dehydrated dogs 
rehydrated over 24 hours with standard fluid therapy. Strong correlation was observed 
between serum SDMA and creatinine concentrations in these dogs and SDMA was seen to 
normalise to within reference interval following rehydration (Choi et al. 2017). These results 
indicate, as would be expected of a marker of GFR, that SDMA can be influenced by pre-
renal factors and volume status and highlights the importance of performing concurrent urine 
specific gravity to assess urine concentrating ability whenever evaluating a marker of GFR 
such as SDMA or creatinine. 
  
Sensitivity of symmetric dimethylarginine for the diagnosis of chronic kidney disease 
In a recent study which measured GFR, Scr and serum SDMA in 21 geriatric cats with CKD 
and 21 healthy geriatric cats, the upper reference interval for SDMA (14ug/dl) corresponded 
to a GFR of 1.47ml/min/kg, a 24% decrease from the median GFR of healthy 
controls (Hall et al. 2014a). In a similar study of 19 dogs with CKD and 20 
healthy controls, the upper reference limit for SDMA corresponded to a GFR decrease of 
49% from median of healthy controls (Hall et al. 2016c). One possible explanation for this 
discrepancy between species could be the clinically healthy populations used to establish 
reference intervals. Without GFR measurements from these reference populations, it is not 
possible to know if animals were included that had reduced renal function, and if so, if the 
number of animals with reduced GFR differed between the dog and cat populations.   
There are a number of studies evaluating the sensitivity of serum SDMA as a marker for 
detection of early CKD and comparing it to Scr. Importantly, studies suggest that SDMA 
detects a decrease in GFR prior to Scr, when based on the established reference 
limits. In a study of 8 male adolescent XHLN dogs with rapidly progressing CKD, serum 
SDMA increased above reference interval an average of 5 weeks prior to an increase 
in Scr, based on their respective reference limits (Nabity et al. 2015)In a study of Beagle 
colony dogs with naturally occurring CKD, serum SDMA was elevated an average of 
9.8 months prior to elevation of Scr (Hall et al. 2016c). Similarly, in a study of 21 
geriatric laboratory cats with naturally occurring CKD, SDMA was elevated an average of 17 
months prior to elevation of creatinine above the upper reference interval of 186 umol/L 
(2.1 mg/dl) (Hall et al. 2014a). 
In the feline study, using a decrease of greater than 30% GFR from the median of healthy 
controls as a significant decrease in GFR, SDMA had 100% sensitivity, 91 % specificity, 
100% negative predictive value and 86% positive predictive value (Hall et al. 2014a.). The 
perfect sensitivity and negative predictive value indicates that cats with SDMA within 
reference interval (≤14 ug/dl) had a normal GFR, but that an elevation in SDMA above 
reference interval (>14 ug/dl) may detect a decrease in GFR of less than 30% in 14% of 
cases. In comparison, the upper reference limit for Scr used in this study 
was 186 umol/L (2.1 mg/dl), this had a 100% specificity and positive predictive 
value, but sensitivity was 17% and negative predictive value was 70%. The perfect 
specificity and positive predictive value indicates that cats with elevation of Scr above 
reference interval (> 186umol/L, 2.1mg/dl) all had a decrease in GFR of greater than 
30%. However, poor sensitivity means that many cats with creatinine within reference 
interval (≤ 186 umol/L, 2.1 mg/dl) may also have a decrease in GFR of greater than 
30% and remain undetected by this upper reference limit. Of interest, the clinically 
healthy cats in this study had Scr of less than 141 µmol/L (1.6 mg/dl) with 
a mean of 106 µmol/L (1.2 mg/dl). Specificity and sensitivity of a clinical test is based on 
reference limits, which are based on the central 95% of a healthy reference population used 
by a specific laboratory. Using a lower cut off below the laboratory reference 
interval for Scr, which reflected the Scr of the clinically healthy cats in the study, would have 
improved the sensitivity of creatinine, although would not necessarily have meant 
that Scr outperformed SDMA in this situation. Similarly, a recent prospective study of 62 
non-azotemic dogs with a clinical suspicion of CKD, observed that elevation 
of SDMA above reference interval (>14 µg/dl) was more sensitive than elevation 
of creatinine above reference interval (>125 umol/L, 1.4 mg/dl) at detecting a 40% decrease 
in GFR from a breed specific reference interval (72%, 25.6% respectively). However, SDMA 
generated false positive results in 32% of cases compared to 100% specificity 
of creatinine (Pelligand et al. 2017). Subsequently, a recent study of 97 client owned 
clinically stable dogs with or without CKD, assessed the overall performance of creatinine, 
SDMA and cystatin C as markers of decreased GFR measured  by scintigraphy (mGFR) and 
found that, although the diagnostic performance of cystatin C was inferior to both creatinine 
and SDMA, overall performance of creatinine and SDMA as markers of 
decreased mGFR were the same (Pelander et al. 2019). Usingpredefined cut-offs of 14 
µg/dL for SDMA and 115 µmol/L for creatinine, a cut-off currently used clinically within the 
study hospital, resulted in almost exactly the same sensitivity and specificity (90% specificity 
90% sensitivity and 87% specificity and 90% sensitivity respectively) for detection of an 
abnormal mGFR (<30.8 mL/min/L). The authors concluded that SDMA had no overall 
diagnostic benefit over creatinine and would be more suitably used as an adjunct to 
creatinine for diagnosis of reduced GFR.  
One study has assessed the diagnostic utility of SDMA for detecting CKD in the specific 
context of canine leishmaniosis (Torrent et al. 2018).  Proteinuric nephropathy, as a result of 
glomerular damage from high levels of circulating immune complexes, can initially manifest 
as proteinuria, progressing to excretory dysfunction with decreased GFR and hypertension 
resulting in progression of CKD. The severity of renal lesions in canine leishmaniosis is 
currently classified by UPC and creatinine concentrations. Torrent and 
colleagues (2018) aimed to determine whether SDMA was increased in dogs with 
leishmaniosis. Fifty-three dogs with Leishmaniosis, 39 of whom had a 6 month follow up, 
were compared to 41 healthy controls. Increased UPC, SDMA and creatinine concentrations 
above their respective reference intervals were found in 47.1%, 15.1% and 9.4% of dogs 
with leishmaniosis on the day of diagnosis and the median of all 3 parameters were found to 
be significantly higher in those dogs that went on to develop CKD compared to those who 
did not. However, no advantage for the use of SDMA in predicating CKD compared to the 
use of UPC or creatinine concentrations was demonstrated.    
These studies together highlight that SDMA has an exponential relationship with GFR similar 
to that of creatinine. On a clinical basis, in some cases, it does appear to detect changes in 
renal function earlier than could be detected by creatinine outside the reference 
interval and therefore can have utility as an early marker of CKD. 
  
Symmetric dimethylarginine and IRIS staging 
 IRIS guidelines were first modified to include serum SDMA concentration in 2015 and 
updated in line with current research in 2019. The recommendations include how to interpret 
SDMA in all stages of CKD. In patients with Stage 2 and 3 CKD based 
on blood creatinine concentrations, it is suggested that SDMA concentrations over the 
threshold of 25 µg/dl in cats or 35 µg/dl in dogs and 38 µg/dl in cats or 54 µg/dl in 
dogs respectively  indicates an underestimation of the degree of renal dysfunction and 
guidelines advise that treatment recommendations for the subsequent IRIS stage should 
be used (IRIS 2019). This is based on the concept that SDMA is not influenced by muscle 
mass and therefore will provide a more accurate reflection of GFR in patients with reduced 
muscle condition. Use of SDMA in this manner provides helpful information, particularly 
where clinicians feel less comfortable extrapolating the implications of sarcopenia on 
reported Scr concentrations.  
Where SDMA may be of particular value is in the identification of those animals in early non-
azotaemic CKD. IRIS guidelines suggest that a persistent mild increase of SDMA above 
reference interval (i.e. >14 and < 18 µg/dl on at least two occasions) with a creatinine of less 
than 125 umol/L (1.4 mg/dl) in dogs  and 140 umol/L (1.6 mg/dl) in cats, may indicate 
reduced renal function (IRIS 2019) and the patient staged as IRIS Stage 1. Those with a 
more severe increase in SDMA (persistently > 18 µg/dL) can be considered IRIS Stage 
2. It should be noted that guidelines specify a ‘persistent’ increase in SDMA, stressing the 
requirement for multiple samples prior to diagnosing a patient as having CKD and 
undertaking IRIS staging. 
It should be noted that although serum SDMA can aid in early diagnosis of CKD, both serum 
SDMA and serum creatinine are biomarkers of GFR only and do not inform on the metabolic 
status of an animal. Neither creatinine or SDMA alone are able to inform about the presence 
of chronic kidney disease- mineral and bone disorder (CKD-MBD) which results 
in derangements in parathyroid hormone (PTH), fibroblast growth factor -23 (FGF-23), 25-
dihydroxyvitamin D, serum calcium and phosphate (Moe et al. 2006).   A recent study aiming 
to identify a safe level of dietary phosphate in adult cats demonstrated significant increases 
from baseline in FGF23 after 2 weeks on a high phosphate test diet. However,  no significant 
increase in creatinine or SDMA concentrations was seen until 13 to 21 weeks on diet, at 
which time 3 cats had developed CKD, having both elevated creatinine and 
SDMA concentrations above reference interval (Alexander et al. 2019). Further research is 
therefore required to establish the derangements in phosphate homeostasis that can be 
identified with stageCKD on the basis of normal creatinine but a persistent elevation in 
SMDA where clinical intervention i.e. dietary modification may be recommended. 
  
Symmetric dimethylarginine, dietary intervention and progression of chronic kidney 
disease 
SDMA is a useful screening tool for early detection of decreased kidney function 
however, its use as a monitoring tool for progression of CKD is not as well established. To 
date there are no studies that have specifically evaluated whether SDMA is a superior 
marker for monitoring change in renal function or progression of disease in CKD 
patients although it could be hypothesised that this may be the case, particularly with 
continued weight and muscle loss with advancing disease and the known effect that this will 
have on Scr. There have however, been several studies that have begun to evaluate the 
impact of dietary intervention in either geriatric or IRIS stage 1 dogs and cats and 
the nutritional effect on SDMA and Scr in this context. 
Feeding a phosphate and protein restricted diet is the primary intervention in canine and 
feline CKD shown to provide survival advantage and slow progression of disease (Elliott et 
al. 2000; Ross et al. 2006). Historically, serial creatinine measurements are routinely used to 
monitor progression (Sparkes et al. 2016). In dietary intervention studies in clinically healthy 
geriatric dogs and cats, some of which were suspected to have IRIS stage 1 CKD, feeding 
test diets containing functional lipids, antioxidants and high quality protein have 
demonstrated that this resulted in significant decreases in variable combinations of renal 
function markers including SDMA and creatinine when compared to owners choice 
diets (Hall et al. 2016a; Hall et al. 2016b). In these studies, the authors speculate that 
improvement in renal function secondary to the effect of the test diet, may explain the 
stability of, or decrease in, circulating SDMA concentrations. However, no direct GFR 
assessments were performed in these studies to confirm this, nor were evaluations 
performedo explore the significance of changes in Scr in the face of stable serum SDMA. 
The true protein concentrations of test and owner diets are difficult to determine from these 
publications. 
In human medicine, it is generally accepted that the rate of SDMA production is relatively 
constant with little biological variation in the healthy individual (Blackwell et al. 2007). 
However, there is evidence in humans to support that there may be an association between 
whole body protein synthesis and catabolism of protein and SDMA 
concentrations (Marliss et al. 2006) such that protein turnover could play an important role in 
regulating plasma levels of methylarginines and particularly in patients with end stage renal 
disease (Cupisti et al. 2009). This is of interest when assessing the significance of changes 
in serial SDMA measurements from an individual where nutritional status or disease process 
may have altered protein synthesis or catabolism, and when comparing SDMA between 
groups with differing nutritional status. It should be remembered that Scr will be substantially 
influenced by muscle synthesis and catabolism and therefore is not an ideal marker in this 
regard. Therefore, it can be speculated that, even if SDMA is to some extent influenced by 
protein turnover, it may still prove superior to Scr. However, a better understanding of non-
renal influences on circulating SDMA including dietary intervention (i.e. protein and 
phosphate restricted renal diets) and changes in serum SDMA concentration over time 
in CKD is required to determine whether serial SDMA measurement is a superior monitoring 
tool for canine and feline CKD than serial assessment of sCr. 
  
Symmetric dimethylarginine and acute kidney injury 
To date, the majority of research into SDMA in veterinary medicine has focused on SDMA in 
the context of CKD. However, more recently the use of SDMA in diagnosing AKI has been 
explored. In a recent study, comparing serum SDMA and Scr of healthy dogs with dogs 
in IRIS CKD stage 2 and AKI grade II (Scr 141-220 umol/L, 1.7-2.5 mg/dl) or above, 
median SDMA concentration were 8.5 µg/dl, 35 µg/dl and 39.5 µg/dl respectively (Dahlem et 
al. 2017). Serum SDMA concentrations were significantly higher in dogs with AKI (P< .0001) 
or CKD (P< .0001) in comparison with healthy dogs although there was no significant 
difference between AKI and CKD dogs. Scr concentration was significantly higher in dogs 
with AKI (583 umol/L, 6.6 mg/dl) compared to dogs with CKD (318 umol/L, 3.6 mg/dL, P= 
.0002) and in both groups when compared to healthy controls (80 umol/L, 0.9 mg/dl). This 
study indicates that, as expected, SDMA is a marker of GFR and is therefore increased in 
patients with AKI. It emphasises that the differentiation of azotaemic AKI from CKD must be 
made on the basis of other parameters, such as historical information, rather than on the 
severity of decline in renal function. Interestingly, creatinine appeared to be able to 
differentiate the AKI and CKD groups, however, without direct GFR measurement it is 
impossible to say whether the variability in Scr reflects true differences in renal function or 
could be accounted for by differences in, for example, muscle mass. This study does 
not allow a definitive conclusion to be made in terms of superiority of either marker for the 
detection of AKI or CKD. In particular, the lack of patients with hospital acquired AKI meant 
that evaluation of SDMA as a marker of grade I AKI was not possible and warrants 
exploration. Given that hospital acquired AKI patients may have more normal body condition 
(dependent on their underlying disease process) then it could be speculated that there may 
be less difference between Scr and SDMA for the detection of early AKI. Further studies, are 
warranted to explore this concept and will become more feasible with the introduction of bed-




SDMA is a useful endogenous marker of GFR in small animal practice. The apparent lack 
of influence from muscle mass makes SDMA a useful tool for assessing renal function in 
patients with low muscle mass where Scr has limitations. However, further studies are 
needed to explore the influence of other non-renal factors. Current research supports the 
use of SDMA as a screening test for detection of early CKD according to IRIS 
guidelines typically performed in conjunction with Scr and urinalysis including urine specific 
gravity. However further research is needed to establish whether SDMA is a more sensitive 
tool for monitoring and predicting disease outcome, fully understanding how concurrent 
disease may influence SDMA concentrations, and how best to manage patients where 
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Figure 1 Curvilinear relationship between GFR and serum creatinine 
 
